VEGF as a potential target for therapeutic intervention in depression

Warner-Schmidt, Jennifer L.; Duman, Ronald S.

doi:10.1016/j.coph.2007.10.013

Cited by 135 publications

(101 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, either peripheral and central nervous system adverse events have been sporadically reported in patients who have received treatment regimens containing bevacizumab or other moAbs. 30,31 In our study the occurrence of adverse events appeared to be correlated with bevacizumab dosage and early deaths were all observed in the groups where greater moAb doses (7.5 and 10 mg/kg) were used. The mPEBev regimen showed a powerful antitumor effect fulfilling the statistical target activity of 35% which was fixed by taking in consideration a number of studies reporting the effects of frontline poly-chemotherapy.…”

Section: Discussionmentioning

confidence: 51%

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Correale¹,

Remondo²,

Carbone³

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Correale¹,

Remondo²,

Carbone³

et al. 2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Chronic stress, which caused reduced hippocampal neurogenesis, significantly decreased the expression of VEGF and flk-1 in the granular cell layer (70). Taken together, these findings suggest that VEGF plays an important role in the complex pathways by which diverse environmental stimuli affect behavioral outcomes, and may be a strong candidate as a therapeutic target in depression (71).…”

Section: Neurotrophic Factors Affecting Adult Hippocampal Neurogenesimentioning

confidence: 74%

Adult hippocampal neurogenesis and related neurotrophic factors

Lee¹,

Son²

2009

BMB Reports

202

126

View full text Add to dashboard Cite

New neurons are continually generated in the subgranular zone of the dentate gyrus and in the subventricular zone of the lateral ventricles of the adult brain. These neurons proliferate, differentiate, and become integrated into neuronal circuits, but how they are involved in brain function remains unknown. A deficit of adult hippocampal neurogenesis leads to defective spatial learning and memory, and the hippocampi in neuropsychiatric diseases show altered neurogenic patterns. Adult hippocampal neurogenesis is not only affected by external stimuli but also regulated by internal growth factors including BDNF, VEGF and IGF-1. These factors are implicated in a broad spectrum of pathophysiological changes in the human brain. Elucidation of the roles of such neurotropic factors should provide insight into how adult hippocampal neurogenesis is related to psychiatric disease and synaptic plasticity.

show abstract

“…The study was designed as a Simon's two-stage minimax optimal design to confirm the hypothesis that the mPEBev regimen is active in patients with advanced for the neurogenic and behavioral action of antidepressant in animal models. [34][35][36][37] Both peripheral and central nervous system adverse events however, have already been reported in patients receiving treatment regimens containing bevacizumab. 38 A further study is presently ongoing to evaluate this particular and complex adverse event in patients who receive combination therapies containing bevacizumab for the treatment of different malignancies.…”

Section: Methodsmentioning

confidence: 99%

“…In the majority of patients these symptoms were mild to moderate, selflimiting and easy to control with antidepressants able to inhibit serotonin re-uptake and to enhance both serotonin and VEGF in the hippocampus (sertraline). [34][35][36][37] Brain CT scan and NMR study performed in patients with severe depression excluded the presence of metastases, major vascular lesions or cortical atrophy. All together these results suggest that the occurrence of depression is a direct effect of VEGF depletion empowered by chemotherapy administration.…”

confidence: 99%

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Correale¹,

Botta²,

Basile³

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcinomas, 4 undifferentiated carcinomas), were enrolled. They received cisplatin (30 mg/sqm, days 1-3), oral etoposide (50 mg, days 1-15) and bevacizumab (5 mg/kg, day 3) every 3 weeks (mPEBev regimen). Patients who achieved an objective response or stable disease received maintenance treatment with bevacizumab in combination with erlotinib until progression. Grade I-II hematological, mucosal toxicity and alopecia were the most common adverse events. The occurrence of infections (17%), thromboembolic events (4.4%) and severe mood depression (6.7%) was also recorded. A partial response was achieved in 31 (68.8%) patients, disease remained stable in 8 (17.8%) and disease progressed in 6 (13.3%) with a progression-free-survival of 9.53 months (95% CI, 7.7-11.46). Our bio-chemotherapy regimen resulted very active in advanced NSCLC, however, the toxicity associated with the treatment requires strict selection of the patients to enroll in future studies. © 2011 Landes Bioscience

show abstract

VEGF as a potential target for therapeutic intervention in depression

Cited by 135 publications

References 50 publications

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

Adult hippocampal neurogenesis and related neurotrophic factors

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Contact Info

Product

Resources

About